When the United States-Mexico-Canada Agreement was signed in November, it seemed like the Association for Accessible Medicines and other stakeholders faced an uphill battle to alter its provisions. But some members of the US Congress were sympathetic to their arguments, with House Democrats, for example, setting up working groups to engage in further discussions with the US Trade Representative.
And during a recent Senate hearing, some legislators expressed concerns that the USMCA trade pact could limit their options to...
